Broad label approval is 'best possible outcome' for Shield Therapeutics' Feraccru
Proactive Research analyst Emma Ulker discusses what she describes as the best possible outcome for its lead drug Feraccru.
The US Food & Drug Administration (FDA) has approved the treatment for a broad label to treat iron deficiency (ID) in adults, addressing a population many times wider than the iron deficiency anaemia (IDA) indications included in the submission data.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment...FOR OUR FULL DISCLAIMER CLICK HERE